Doseology SciencesDOSEF -16.16%33 Current Ratio is 10.31 as of Mar. 2026, which is 27% below its 10-year median of 14.13. GuruFocus rates DOSEF with a GF Score™ of 33/100 and a GF Value™ of $0.17 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,413 Biotechnology companies, Doseology Sciences ranks better than 78.56% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Doseology Sciences's current ratio for the quarter that ended in Mar. 2026 was 10.31.
Doseology Sciences has a current ratio of 10.31. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Doseology Sciences's Current Ratio or its related term are showing as below:
DOSEF'
s Current Ratio Range Over the Past 10 Years
Min: 1.82 Med: 14.13 Max: 378.67
Current: 10.3
During the past 6 years, Doseology Sciences's highest Current Ratio was 378.67. The lowest was 1.82. And the median was 14.13.
DOSEF's Current Ratio is ranked better than 78.56% of 1413
companies
in the Biotechnology industry
Industry Median: 3.89
vs DOSEF: 10.30
Doseology Sciences (OTCPK:DOSEF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Doseology Sciences Current Ratio Related Terms
Doseology Sciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Doseology Sciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DOSEF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Doseology Sciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Doseology Sciences Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Doseology Sciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Doseology Sciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Doseology Sciences (DOSEF) has a Current Ratio of 10.31 as of Mar. 2026. This is 27% below median its historical median of 14.13. Over the past decade, Doseology Sciences' Current Ratio has ranged from 1.82 to 378.67. According to the industry distribution chart, Doseology Sciences ranks #303 out of 1413 companies in the Biotechnology industry, placing it in the top 21.4%.
Is Doseology Sciences' Current Ratio too high?
Doseology Sciences' current Current Ratio of 10.31 is 27% below median its 10-year median of 14.13. Over the past 10 years, this metric has ranged from a low of 1.82 to a high of 378.67. The Biotechnology industry median Current Ratio is 3.89. Doseology Sciences' value of 10.31 is 165% above this industry median. Based on the distribution chart, Doseology Sciences ranks #303 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Doseology Sciences has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Doseology Sciences' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Doseology Sciences ranks #303 out of 1413 companies for Current Ratio. This places Doseology Sciences in the top 21% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Doseology Sciences' value of 10.31 is 165% above this benchmark. Historically, Doseology Sciences' own Current Ratio has ranged from 1.82 to 378.67 over the past decade. While the company's 10-year median is 14.13 vs. the industry median of 3.89, Doseology Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Doseology Sciences's current Current Ratio of 10.31 is 165% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Doseology Sciences's current Current Ratio is 10.31, which is 27% below median its own 10-year median of 14.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Doseology Sciences stock overvalued right now?
Based on GuruFocus' analysis, Doseology Sciences (DOSEF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.17, compared to a current price of $0.11 — trading 34.1% below its estimated fair value. The current Current Ratio is 10.31, which is 27% below median its 10-year median of 14.13 and 165% above the Biotechnology industry median of 3.89. Doseology Sciences' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Doseology Sciences (DOSEF), the current Current Ratio is 10.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Doseology Sciences (DOSEF) Overvalued in 2026?
Based on GuruFocus' analysis, Doseology Sciences stock appears to be undervalued.
The current stock price of $0.11 is trading 34.1% below its estimated GF Value™ of $0.17.
GuruFocus considers Doseology Sciences to be Possible Value Trap.
Key valuation signals for DOSEF:
Current Ratio: 10.31 (27% below median its 10-year median of 14.13)
GF Value™: $0.17 vs. price of $0.11 (34.1% below fair value)
Industry Position: 165% above the Biotechnology median (#303 of 1413)
No single metric tells the full story. See the DOSEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Doseology Sciences Inc is a diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on the psychedelic and non-psychedelic compounds, also sale of its branded functional mushroom products. It offers cutting-edge therapeutic products and services, with the focus of making a meaningful impact on the mental health pandemic and improving overall health. Geographically earns it revenue from Canada.
33GF Score
Get the complete analysis for DOSEF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DOSEF has been successfully added to your 
